 Secondary Prevention
"Secondary Prevention" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prevention of recurrences or exacerbations of a disease or complications of its therapy.
| Descriptor ID |
D055502
|
| MeSH Number(s) |
E02.897 N02.421.726.825 N06.850.780.750
|
| Concept/Terms |
Secondary Prevention- Secondary Prevention
- Prevention, Secondary
- Preventions, Secondary
- Secondary Preventions
- Secondary Disease Prevention
- Disease Prevention, Secondary
- Disease Preventions, Secondary
- Prevention, Secondary Disease
- Preventions, Secondary Disease
- Secondary Disease Preventions
Relapse Prevention- Relapse Prevention
- Prevention, Relapse
- Preventions, Relapse
- Relapse Preventions
Early Therapy- Early Therapy
- Early Therapies
- Therapies, Early
- Therapy, Early
|
Below are MeSH descriptors whose meaning is more general than "Secondary Prevention".
Below are MeSH descriptors whose meaning is more specific than "Secondary Prevention".
This graph shows the total number of publications written about "Secondary Prevention" by people in this website by year, and whether "Secondary Prevention" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 4 | 4 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 6 | 6 | | 2008 | 0 | 4 | 4 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 11 | 11 | | 2011 | 1 | 5 | 6 | | 2012 | 2 | 8 | 10 | | 2013 | 4 | 7 | 11 | | 2014 | 3 | 8 | 11 | | 2015 | 6 | 6 | 12 | | 2016 | 6 | 15 | 21 | | 2017 | 7 | 10 | 17 | | 2018 | 9 | 10 | 19 | | 2019 | 6 | 9 | 15 | | 2020 | 3 | 9 | 12 | | 2021 | 2 | 6 | 8 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 4 | 4 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Secondary Prevention" by people in Profiles.
-
Orjuela KD, Leppert MH, Carroll JD. Navigating the Gray: The Complex Story of PFO Closure Utilization. Circ Cardiovasc Qual Outcomes. 2024 01; 17(1):e010581.
-
Bonaca MP, Les?n E, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Duong M, Maggioni AP, Ariza-Sol? A, Ten Berg J, Storey RF. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14; 9(8):701-708.
-
Gupta K, Mehta H, Kim H, Stebbins A, Wruck LM, Mu?oz D, Effron MB, Anderson RD, Pepine CJ, Jain SK, Girotra S, DeWalt DA, Whittle J, Benziger CP, Farrehi P, Zhou L, Knowlton KU, Polonsky TS, Bradley SM, Harrington RA, Rothman RL, Jones WS, Hernandez AF. Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Am Heart J. 2023 10; 264:31-39.
-
Skrzynski CJ, Bryan AD, Hutchison KE. Mindfulness mechanisms in alcohol use: Comparing top-down and bottom-up processes. Psychol Addict Behav. 2024 Feb; 38(1):92-100.
-
Skrzynski CJ, Karoly H, Ellingson JM, Hagerty SL, Bryan AD, Hutchison KE. Comparing the Efficacy of Mindfulness-Based Relapse Prevention Versus Relapse Prevention for Alcohol Use Disorder: A Randomized Control Trial. J Stud Alcohol Drugs. 2023 07; 84(4):560-569.
-
Pollack CV, Steg PG, James S, Jolly S, Kosiborod M, Bonaca MP. International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular Care. Crit Pathw Cardiol. 2022 09 01; 21(3):114-122.
-
Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, Derumeaux G, Furlan AJ, Herrmann HC, J?ni P, Kim JS, Koethe B, Lee PH, Lefebvre B, Mattle HP, Meier B, Reisman M, Smalling RW, Soendergaard L, Song JK, Mas JL, Thaler DE. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. JAMA. 2021 12 14; 326(22):2277-2286.
-
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, ?pinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 09 07; 10(17):e020446.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|